

# **LDH-P** – SCE Pyruvate $\rightarrow$ Lactate Instructions for use (IFU)



# CE

#### ORDERING INFORMATION

|                           | Code          | Composition                |
|---------------------------|---------------|----------------------------|
|                           | REF B75182517 | n° 10 vials x 9 mL (R.A)   |
| R E E                     | الديماديم بين | n° 1 vials x 10 mL (R.B)   |
| OPEN<br>(ONELAI<br>INDIKO | DEE D75400540 | n° 15 vials x 4,5 mL (R.A) |
| _                         | REF B75182518 | n° 1 vials x 8 mL (R.B)    |
| m                         | REF B81180241 | n° 3 vials x 23 mL (R.A)   |
| CHEMILAB                  | D01100241     | n° 1 vials x 8 mL (R.B)    |
| HE.                       | DEE D04400040 | n° 5 vials x 28 mL (R.A)   |
| 0                         | REF B81180242 | n° 2 vials x 8 mL (R.B)    |

## INTENDED USE

Product for use in the quantitative determination in vitro of the LDH activity in human serum. The results of the test must always be interpreted in conjunction with the clinical context. FOR PROFESSIONAL USE ONLY.

## **CLINICAL SIGNIFICANCE**

LDH is an enzyme which catalyzes the reduction of pyruvic acid to lactic acid. The wide-spread diffusion of LDH in the organism explains why this enzyme increases in the serum in numerous pathological conditions involving various different tissues, such as the liver (viral hepatitis), cardiac muscle (myocardial infarction), skeletal muscle and kidneys. The kidney is the organ containing the highest concentration of the enzyme, followed by the myocardium, skeletal muscle, spleen, liver and lungs. LDH activity in the serum is determined by a group of five isoenzymes deriving from different tissues. LDH activity can be determined by measuring the conversion of lactate to pyruvate or pyruvate to lactate.

## PRINCIPLE OF THE METHOD

Method SCE Pyruvate  $\rightarrow$  Lactate. LDH catalyzes the following reaction:

## Storage and stability



stored at 2-6 ° C avoiding direct light, the reagents are stable until the expiration date printed on the label.

## Concentrations

| Reagent A: Substrate buffer |       |        |
|-----------------------------|-------|--------|
|                             | Conc. | U.M.   |
| TRIS buffer pH 7.4 ± 0.2    | 50.1  | mmol/L |
| Sodium pyruvate             | 1.20  | mmol/L |
| EDTA                        | 5.00  | mmol/L |
| Sodium azide                | 13.8  | mmol/L |
| Reagent B: NADH             |       |        |
|                             | Conc. | U.M.   |
| TRIS buffer pH 10.2 ± 0.2   | 50.0  | mmol/L |
| NADH (from yeast)           | 1.80  | mmol/L |
| Sodium azide                | 13.8  | mmol/L |

<sup>\*</sup> Warning: - The product is not classified, according to CLP regulation

## Reagents included in the kit

The reagent is described above.

## Materials required but not supplied in the kit

Controls, calibrators and pipettes with adequate volume

## PRECAUTIONS and WARNINGS

- 1. Reagents and waste materials shall be disposed of in accordance with Community waste provisions or national or regional provisions.
- Reagents may contain non-active components such as preservatives and detergents.The total concentration of these components is below the limits set out in Regulation 1272/2008 EC and subsequent amendments and additions.
- 3. It is recommended that the reagent be handled in accordance with the rules of good laboratory practice and that appropriate personal protective equipment be used.
- 4. Do not use the reagent if it is visibly degraded (e.g. presence of corpuscles)
- 5. All human samples shall be handled and disposed of as potentially infectious
- 6. The kit should only be used by qualified and properly trained technical personnel.
- 7. Diagnoses shall be carried out exclusively by authorised and qualified personnel.
- 8. Comply with national directives on occupational safety and quality assurance.
- 9. Use equipment that complies with current regulations.

#### Reporting of serious incidents

Please inform the manufacturer (through your distributor) and the competent authority of the member state of the European Union in which the user and/or patient is established, of cases of serious incident that has occurred in relation to the device. For other jurisdictions, reports of serious incidents must be made in accordance with the regulatory requirements of the home Member State. By reporting serious incidents, you help provide more information about the safety of your in vitro medical diagnostic device.

#### **PROCEDURE**

## **Quality control**

Control sera with a known titer of LDH are commercially available for quality control, with values and confidence limits included. Sclavo Diagnostics Normal and pathological control sera are available: Clinicontrol N 5x5mL cod. B35181700 and Clinicontrol A 5x5mL code B35181701. The values obtained must be within the acceptability range.

#### Calibration

For calibration use the "Calibrator serum Sclavo" code B35181702.

#### Traceability

The Lactic Dehydrogenase concentration is reported in the package insert supplied with the "Calibrator Serum".

#### SAMPLI

## Type of sample and storage

Use fresh non-haemolysed serum samples. LDH is stable in serum 1 week at 4-20°C and one month at -20°C.

#### REAGENT PREPARATION

## Add 1 volume of Reagent B to 9 volume of Reagent A and mix gently.

After reconstitution the reagent is stable for 15 days if closed and stored at 2-8°C. A slight variation in colour among batches, does not affect test results.

#### Automation

The kit can be used with all automatic analyzers that can meet the operating conditions of the reagent while maintaining the volumetric ratios R1 / R2 / C. Validated applications are available for Sclavo Konelab® - Indiko® and CHEMILAB instruments. Applications not approved by Sclavo Diagnostics do not guarantee the performance of the reagent and must therefore be approved under the responsibility of the user.

## MANUAL METHOD

The kit, in Open format, can be used manually through the use of spectrophotometer or photometer with the following parameters:

## Reaction conditions

Wavelength (primary): 340 nm Temperature: 37°C

Reaction Kinetic (decreasing reaction)

## Technique - Monoreactive

Bring the reagents to reaction temperature and operate away from direct light.

| <b>J J</b>    | U.M. | I. Calibrator Serum San |      |
|---------------|------|-------------------------|------|
| Reagent (A+B) | μL   | 1000                    | 1000 |
| Calib. Serum  | μL   | 20                      | -    |
| Sample        | uL   | -                       | 20   |

Mix gently and incubate at reaction temperature for 30 sec.

After the incubation, read the absorbance at 340 nm. Repeat readings at 30 seconds or 1-minute intervals. Recording a minimum of 3 absorbance changes is recommended. Determine the mean  $\Delta$  0.D./min.

The reaction volumes can be varied proportionally without altering the result.

## Results:

## **Manual Method**

Calculation of Lactic Dehydrogenase concentration:

 $\frac{\Delta \text{ O.D. sample}}{\Delta \text{ O.D. Calib. serum}} x \text{ Calib. serum conc. (U/L)} = \text{U/L LDH}$ 

## Automation

The results are automatically calculated by the analyzer based on the calibration line. The analyzer automatically performs calibration in accordance with the method protocol. The calibration line is calculated automatically by the different instruments.

Calculation of the results obtained using a multiplication factor





# **LDH-P** – SCE Pyruvate → Lactate Instructions for use (IFU)



CE

 $\Delta$  O.D./min x K-factor\* = U/L of LDH

Explanation of the calculation:

Vt x 1000

= K - factor \* x  $\triangle$  O.D./min. = U/L LDH

M.E.C. x O.P. x Vc

\*K-factor = 8199

where:

U/L = activity in serum in international units

 $\Delta$  O.D./min. = variation in absorbance per minute

 $Vt = total reaction volume (\mu L)$ 

1000 = conversion to the concentration per liter

M.E.C. = micromolar extinction coefficient of NADH 6.22 cm <sup>2</sup>/ µmol at 340 nm

O.P. = optic path (1cm)

Vc = sample volume in the mixture (µI)

## REFERENCE RANGE

Serum: 208-378 U/L

Each laboratory must establish its own normal values on the basis of its local population.

## ANALYTICAL CHARACTERISTICS / PERFORMANCE

Linearity

The method is linear up to 2100 U/L at 340 nm.

#### Accuracy / Recovery

Commercial control sera were analyzed with the kit in question following the guidelines of the CLSI protocol. The data obtained are shown in the table below.

| Range | Replicates | Mean | ES medio | CV%  | Recovery |
|-------|------------|------|----------|------|----------|
| Basso | 5          | 247  | 1.77     | 1.61 | 101 %    |
| Alto  | 5          | 894  | 2.31     | 0.58 | 100.5 %  |

#### Interferences

| Interference  | Limits     |
|---------------|------------|
| Triglycerides | 2000 mg/dL |
| Ascorbic acid | 30 mg/dL   |

## Precision of the method

| Within-run precision  |      |      |       |          |     |
|-----------------------|------|------|-------|----------|-----|
| Range                 | U.M. | Mean | S.D.  | C.V. (%) | No. |
| Low                   | U/L  | 232  | 6.14  | 2.65     | 30  |
| High                  | U/L  | 620  | 10.82 | 1.75     | 30  |
| Between-run precision |      |      |       |          |     |
| Range                 | U.M. | Mean | S.D.  | C.V. (%) | No. |
| Low                   | U/L  | 236  | 8.80  | 3.73     | 20  |
| High                  | U/L  | 583  | 26.07 | 4.47     | 20  |

## Limit of Sensitivity

The Sensitivity limit has been measured using serial dilutions of high concentrated sera. The smallest detectable concentration is about 8.2 U/L of Lactic Dehydrogenase.

## Comparison between methods

The method was compared with a similar commercial method analysing 20 human sera. The correlation data between the two methods are reported in the table below.

| Parameter              | Estimation |
|------------------------|------------|
| Intercept              | 6.08       |
| Slope                  | 0.901      |
| Correlation Coeff. (R) | 0.999      |

| Symbols used in IFU and Packaging        |                        |  |  |  |
|--|------------------------|--|--|--|
| In vitro diagnostic medical device vitro | Manufacturer           |  |  |  |
| REF Catalogue Number                     | ☐ Instruction for use  |  |  |  |
| Lot Number                               | Temperature limitation |  |  |  |
| Expiration date                          |                        |  |  |  |

## **REFERENCES**

- The Committee on Enzymes of the Scandinavian Society for Clinical Investigation and Clinical Physiology. Scand J Clin Lab Invest 1974; 32: 291
- Amador E, Wacker WE (1965) Enzymatic methods used for diagnosis. Methods Biochem Anal.;13:265-356.
- Clinical Laboratory Standards Institute (CLSI). User Verification of Performance for Precision and Trueness; Approved Guideline – Second Edition. EP15-A2.
- Clinical Laboratory Standards Institute (CLSI). Evaluation of Precision Performance of Quantitative Measurements Methods; Approved Guideline – Second Edition. EP05-A2.
- Clinical Laboratory Standards Institute (CLSI). Measurement Procedure Comparison and Bias Estimation Using Patient Samples; Approved Guideline – Third Edition. EP09-A3.
- Clinical Laboratory Standards Institute (CLSI). Evaluation of Detection Capability for Clinical Laboratory Measurement Procedures, 2nd Edition – EP17.
- Clinical Laboratory Standards Institute (CLSI). Interference Testing in Clinical Chemistry, – Third Edition. - EP07.
- Clinical Laboratory Standards Institute (CLSI). Evaluation of Linearity of Quantitative Measurement Procedures, 2nd Edition - EP06.

| REVISION | DATE    | CHANGE                                      |
|----------|---------|---|
| Rev.A    | 01/2023 | New Issue for IVDR Regulation (UE) 2017/746 |
|          |         | compliance                                  |

